Directive 1965/65 - Approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products - Main contents
Please note
This page contains a limited version of this dossier in the EU Monitor.
Contents
official title
Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal productsLegal instrument | Directive |
---|---|
Number legal act | Directive 1965/65 |
CELEX number i | 31965L0065 |
Document | 26-01-1965 |
---|---|
Publication in Official Journal | 09-02-1965; Special edition in Greek: Chapter 13 Volume 001,Special edition in Danish: Chapter I Volume 1965-1966,Special edition in Swedish: Chapter 13 Volume 001,Special edition in English: Chapter I Volume 1965-1966,Special edition in Portuguese: Chapter 13 Volume 001,Special edition in Finnish: Chapter 13 Volume 001,OJ P 22, 9.2.1965,Special edition in Spanish: Chapter 13 Volume 001 |
Effect | 03-02-1965; Entry into force Date notif. |
End of validity | 17-12-2001; Repealed by 32001L0083 |
Transposition | 31-12-1966; See Art 22 ET 366L0454 Art 1 03-02-1970; See Art 24 |
Notification | 03-02-1965 |
|
Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products
Official Journal 022 , 09/02/1965 P. 0369 - 0373
Finnish special edition: Chapter 13 Volume 1 P. 0067
Swedish special edition: Chapter 13 Volume 1 P. 0067
Danish special edition: Series I Chapter 1965-1966 P. 0017
English special edition: Series I Chapter 1965-1966 P. 0024
Greek special edition: Chapter 13 Volume 1 P. 0025
Spanish special edition: Chapter 13 Volume 1 P. 0018
Portuguese special edition Chapter 13 Volume 1 P. 0018
COUNCIL DIRECTIVE of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products (65/65/EEC)
THE COUNCIL OF THE EUROPEAN ECONOMIC COMMUNITY,
Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;
Having regard to the proposal from the Commission;
Having regard to the Opinion of the European Parliament (1);
Having regard to the Opinion of the Economic and Social Committee (2);
Whereas the primary purpose of any rules concerning the production and distribution of proprietary medicinal products must be to safeguard public health;
Whereas, however, this objective must be attained by means which will not hinder the development of the pharmaceutical industry or trade in medicinal products within the Community;
Whereas trade in proprietary medicinal products within the Community is hindered by disparities between certain national provisions, in particular between provisions relating to medicinal products (excluding substances or combinations of substances which are foods, animal feeding-stuffs or toilet preparations) ; and whereas such disparities directly affect the establishment and functioning of the common market;
Whereas such hindrances must accordingly be removed ; and whereas this entails approximation of the relevant provisions;
Whereas, however, such approximation can only be achieved progressively ; and whereas priority must be given to eliminating the disparities liable to have the greatest effect on the functioning of the common market;
HAS ADOPTED THIS DIRECTIVE:
CHAPTER I Definitions and scope
Article 1
For the purposes of this Directive, the following shall have the meanings hereby assigned to them; 1. Proprietary medicinal product:
Any ready-prepared medicinal product placed on the market under a special name and in a special pack.
-
2.Medicinal product:
Any substance or combination of substances presented for treating or preventing disease in human beings or animals.
Any substance or combination of substances which may be administered to human beings or animals with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in human beings or in animals is likewise considered a medicinal product.
-
(1)OJ No 84, 4.6.1963, p. 1571/63. (2) OJ No 158, 16.10.1964, p. 2508/64. 3. Substance:
Any matter irrespective of origin which may be: - human, e.g.
human blood and human blood products;
-
-animal, e.g.
micro-organisms, whole animals, parts of organs, animal secretions, toxins, extracts, blood products, etc;
-
-vegetable, e.g.
micro-organisms, plants, parts of plants, vegetable secretions, extracts, etc;
-
-chemical, e.g.
elements, naturally occurring chemical materials and chemical products obtained by chemical change or synthesis.
Article 2
The provisions of Chapters II to V shall apply only to proprietary medicinal products for human use intended to be placed on the market in Member States.
CHAPTER II Authorisation to place proprietary medicinal products on the market
Article 3
No proprietary medicinal product may be placed on the market in a Member State unless an...
More
This text has been adopted from EUR-Lex.
This dossier is compiled each night drawing from aforementioned sources through automated processes. We have invested a great deal in optimising the programming underlying these processes. However, we cannot guarantee the sources we draw our information from nor the resulting dossier are without fault.
This page is also available in a full version containing the legal context, de Europese rechtsgrond, other dossiers related to the dossier at hand and the related cases of the European Court of Justice.
The full version is available for registered users of the EU Monitor by ANP and PDC Informatie Architectuur.
The EU Monitor enables its users to keep track of the European process of lawmaking, focusing on the relevant dossiers. It automatically signals developments in your chosen topics of interest. Apologies to unregistered users, we can no longer add new users.This service will discontinue in the near future.